References
1. Puljic A, Kim E,
Page J, et al. The risk of infant and fetal death by each
additional week of expectant management in intrahepatic cholestasis of
pregnancy by gestational age. Am J Obstet Gynecol 2015;212:667
e1-5.
2. Reyes H, Gonzalez
MC, Ribalta J, et al. Prevalence of intrahepatic cholestasis
of pregnancy in Chile. Ann Intern Med 1978;88:487-93.
3. Lammert F,
Marschall HU, Glantz A, Matern S.
Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis
and management. J Hepatol 2000;33:1012-21.
4. Kenyon AP, Piercy
CN, Girling J, Williamson C, Tribe RM,
Shennan AH. Obstetric cholestasis, outcome with active
management: a series of 70 cases. BJOG 2002;109:282-8.
5. Lee RH, Goodwin
TM, Greenspoon J, Incerpi M. The prevalence of
intrahepatic cholestasis of pregnancy in a primarily Latina Los Angeles
population. J Perinatol 2006;26:527-32.
6. Lee RH, Kwok KM,
Ingles S, et al. Pregnancy outcomes during an era of aggressive
management for intrahepatic cholestasis of pregnancy. Am J
Perinatol 2008;25:341-5.
7. Rook M, Vargas J,
Caughey A, Bacchetti P, Rosenthal P,
Bull L. Fetal outcomes in pregnancies complicated by
intrahepatic cholestasis of pregnancy in a Northern California cohort.PLoS One 2012;7:e28343.
8. Fisk NM, Storey
GN. Fetal outcome in obstetric cholestasis. Br J Obstet Gynaecol1988;95:1137-43.
9. Alsulyman OM,
Ouzounian JG, Ames-Castro M, Goodwin TM.
Intrahepatic cholestasis of pregnancy: perinatal outcome associated with
expectant management. Am J Obstet Gynecol 1996;175:957-60.
10. Geenes V,
Chappell LC, Seed PT, Steer PJ,
Knight M, Williamson C. Association of severe
intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a
prospective population-based case-control study. Hepatology2014;59:1482-91.
11. Oztekin D, Aydal
I, Oztekin O, Okcu S, Borekci R,
Tinar S. Predicting fetal asphyxia in intrahepatic cholestasis
of pregnancy. Arch Gynecol Obstet 2009;280:975-9.
12. Brouwers L,
Koster MP, Page-Christiaens GC, et al. Intrahepatic
cholestasis of pregnancy: maternal and fetal outcomes associated with
elevated bile acid levels. Am J Obstet Gynecol 2015;212:100 e1-7.
13. Van Mil SW,
Milona A, Dixon PH, et al. Functional variants of the
central bile acid sensor FXR identified in intrahepatic cholestasis of
pregnancy. Gastroenterology 2007;133:507-16.
14. Reichert MC,
Lammert F. ABCB4 Gene Aberrations in Human Liver Disease: An
Evolving Spectrum. Semin Liver Dis 2018;38:299-307.
15. Hirvioja ML,
Kivinen S. Inheritance of intrahepatic cholestasis of pregnancy
in one kindred. Clin Genet 1993;43:315-7.
16. Holzbach RT,
Sivak DA, Braun WE. Familial recurrent intrahepatic
cholestasis of pregnancy: a genetic study providing evidence for
transmission of a sex-limited, dominant trait. Gastroenterology1983;85:175-9.
17. Reyes H, Ribalta
J, Gonzalez-Ceron M. Idiopathic cholestasis of pregnancy in a
large kindred. Gut 1976;17:709-13.
18. Eloranta ML,
Heinonen S, Mononen T, Saarikoski S. Risk of
obstetric cholestasis in sisters of index patients. Clin Genet2001;60:42-5.
19. Savander M,
Ropponen A, Avela K, et al. Genetic evidence of
heterogeneity in intrahepatic cholestasis of pregnancy. Gut2003;52:1025-9.
20. Hayashi H,
Takada T, Suzuki H, Onuki R, Hofmann
AF, Sugiyama Y. Transport by vesicles of glycine- and
taurine-conjugated bile salts and taurolithocholate 3-sulfate: a
comparison of human BSEP with rat Bsep. Biochim Biophys Acta2005;1738:54-62.
21. Ito K, Oleschuk
CJ, Westlake C, Vasa MZ, Deeley RG,
Cole SP. Mutation of Trp1254 in the multispecific organic anion
transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters
substrate specificity and results in loss of methotrexate transport
activity. J Biol Chem 2001;276:38108-14.
22. Huusko JM,
Karjalainen MK, Graham BE, et al. Whole exome
sequencing reveals HSPA1L as a genetic risk factor for spontaneous
preterm birth. PLoS Genet 2018;14:e1007394.
23. Sun Y, Li Y,
Chen M, et al. A Novel Silent Mutation in the L1CAM Gene
Causing Fetal Hydrocephalus Detected by Whole-Exome Sequencing.Front Genet 2019;10:817.
24. Dixon PH,
Williamson C. The pathophysiology of intrahepatic cholestasis
of pregnancy. Clin Res Hepatol Gastroenterol 2016;40:141-53.
25. Kamimura K, Abe
H, Kamimura N, et al. Successful management of severe
intrahepatic cholestasis of pregnancy: report of a first Japanese case.BMC Gastroenterol 2014;14:160.
26. Johnston RC,
Stephenson ML, Nageotte MP. Novel heterozygous ABCB4
gene mutation causing recurrent first-trimester intrahepatic cholestasis
of pregnancy. J Perinatol 2014;34:711-2.
27. Dixon PH, van
Mil SW, Chambers J, et al. Contribution of variant alleles of
ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy.Gut 2009;58:537-44.
28. More VR, Cheng
Q, Donepudi AC, et al. Alcohol cirrhosis alters nuclear
receptor and drug transporter expression in human liver. Drug
Metab Dispos 2013;41:1148-55.
29. Que KT, Zhou Y,
You Y, et al. MicroRNA-31-5p regulates chemosensitivity by
preventing the nuclear location of PARP1 in hepatocellular carcinoma.J Exp Clin Cancer Res 2018;37:268.
30. Estiu MC, Monte
MJ, Rivas L, et al. Effect of ursodeoxycholic acid treatment
on the altered progesterone and bile acid homeostasis in the
mother-placenta-foetus trio during cholestasis of pregnancy. Br J
Clin Pharmacol 2015;79:316-29.
31. Bacq Y, le Besco
M, Lecuyer AI, et al. Ursodeoxycholic acid therapy in
intrahepatic cholestasis of pregnancy: Results in real-world conditions
and factors predictive of response to treatment. Dig Liver Dis2017;49:63-69.
32. Piatek K,
Kurzawinska G, Magielda J, et al. The role of ABC
transporters’ gene polymorphism in the etiology of intrahepatic
cholestasis of pregnancy. Ginekol Pol 2018;89:393-97.
33. Ahmad TR,
Haeusler RA. Bile acids in glucose metabolism and insulin
signalling - mechanisms and research needs. Nat Rev Endocrinol2019;15:701-12.
34. Hofmann AF, Roda
A. Physicochemical properties of bile acids and their relationship to
biological properties: an overview of the problem. J Lipid Res1984;25:1477-89.
35. Wang DQ, Tazuma
S, Cohen DE, Carey MC. Feeding natural hydrophilic
bile acids inhibits intestinal cholesterol absorption: studies in the
gallstone-susceptible mouse. Am J Physiol Gastrointest Liver
Physiol 2003;285:G494-502.
36. Aleo MD, Shah
F, He K, Bonin PD, Rodrigues AD. Evaluating
the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in
Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.Chem Res Toxicol 2017;30:1219-29.
Table 1. Forty-two potential pathogenic ABC novel mutations were
identified in 151 Han Chinese with ICP disease.